Company news
Celldex Therapeutics, Inc. news in 2021
Celldex Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
December 7, 2021
Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021
November 11, 2021
Celldex to Participate in Upcoming Investor Conferences
November 10, 2021
Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 8, 2021
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
September 28, 2021
Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
September 22, 2021
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
September 12, 2021
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 4, 2021
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
July 12, 2021
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
July 8, 2021
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
June 3, 2021
Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021
May 31, 2021
Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference
May 25, 2021
Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
April 11, 2021
Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria
March 28, 2021
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
March 28, 2021
Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference
March 4, 2021
Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 21, 2021
Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)
February 21, 2021
Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel
January 3, 2021